Respiratorius is rushing towards patent approval

“The European Patent Office has granted a patent for the new formulation of Respirator drug candidate VAL001. The patent protects an oral formulation of sodium valproate for cancer treatment. It provides market exclusivity for at least 20 years from 2016. Corresponding patents have already been approved in the US, Japan and Canada. The stock surged by over 60 percent on the news.”

Published in Biostock; May 27, 2025